# Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®

> **NCT06504966** · PHASE3 · WITHDRAWN · sponsor: **Xentria, Inc.**

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** MAB-22
- **DRUG:** Prolia®

## Key facts

- **NCT ID:** NCT06504966
- **Lead sponsor:** Xentria, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-10
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision not to proceed with the study.
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06504966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06504966, "Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06504966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*